Rubric Capital Management LP purchased a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 691,170 shares of the company's stock, valued at approximately $5,004,000. Rubric Capital Management LP owned approximately 1.14% of Eupraxia Pharmaceuticals at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $71,000. Bank of America Corp DE boosted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock worth $72,000 after buying an additional 10,059 shares during the last quarter. Aptus Capital Advisors LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter worth approximately $76,000. Guardian Wealth Advisors LLC NC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter worth approximately $76,000. Finally, Geode Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $105,000.
Analyst Ratings Changes
A number of analysts recently commented on EPRX shares. Stifel Nicolaus began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They set a "buy" rating and a $25.00 price target for the company. Wall Street Zen downgraded Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Finally, Zacks Research raised shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Analysis on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Stock Performance
NASDAQ:EPRX opened at $6.17 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 19.31 and a quick ratio of 19.31. The business has a fifty day simple moving average of $6.51 and a two-hundred day simple moving average of $7.33. Eupraxia Pharmaceuticals Inc. has a 1 year low of $5.04 and a 1 year high of $9.32. The company has a market capitalization of $401.17 million, a P/E ratio of -5.88 and a beta of 1.05.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). On average, analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.88 earnings per share for the current year.
Eupraxia Pharmaceuticals Profile
(
Free Report)
Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.
Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.
Further Reading
Want to see what other hedge funds are holding EPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
